Details for Patent: 7,449,464

Which drugs does patent 7,449,464 protect, and when does it expire?

Patent 7,449,464 protects LYNPARZA and is included in two NDAs.

This patent has eighty-five patent family members in thirty-seven countries.

Summary for Patent: 7,449,464

Title:	Phthalazinone derivatives
Abstract:	Compounds of the formula (I): ##STR00001## wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR.sup.X or CR.sup.XR.sup.Y; if X=NR.sup.X then n is 1 or 2 and if X=CR.sup.XR.sup.Y then n is 1; R.sup.X is selected from the group consisting of H, optionally substituted C.sub.1-20 alkyl, C.sub.5-20 aryl, C.sub.3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R.sup.Y is selected from H, hydroxy, amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1 and R.sup.C2 are both hydrogen, or when X is CR.sup.XR.sup.Y, R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R.sup.1 is selected from H and halo.
Inventor(s):	Martin; Niall Morrison Barr (Cambridge, GB), Smith; Graeme Cameron (Cambridge, GB), Jackson; Stephen Philip (Cambridge, GB), Loh; Vincent Junior M (Horsham, GB), Cockcroft; Xiao-Ling Fan (Horsham, GB), Matthews; Ian Timothy Williams (Horsham, GB), Menear; Keith Allan (Horsham, GB), Kerrigan; Frank (Cornwall, GB), Ashworth; Alan (London, GB)
Assignee:	Kudos Pharmaceuticals Limited (Cambridge, GB) Maybridge Limited (Cornwall, GB)
Application Number:	10/876,080
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,449,464
Patent Claim Types: see list of patent claims	Compound; Composition;

United States Patent 7,449,464: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 7,449,464, titled "Phthalazinone derivatives," was granted on November 11, 2008, to Kudos Pharmaceuticals Limited and Maybridge Limited. This patent is significant in the pharmaceutical industry, particularly in the development of new chemical compounds with potential therapeutic applications.

Background and Inventors

The patent was filed on June 24, 2004, by a team of inventors including Niall Morrison Barr Martin, Graeme Cameron Smith, Stephen Philip Jackson, Vincent Junior M. Loh, Xiao-Ling Fan Cockcroft, Ian Timothy Williams Matthews, Keith Allan Menear, Frank Kerrigan, and Alan Ashworth. These inventors are affiliated with various research institutions and pharmaceutical companies in the UK[4].

Scope of the Patent

Chemical Compounds

The patent covers a class of phthalazinone derivatives, which are chemical compounds with specific structural features. These compounds are described by their general formula and the various substituents that can be attached to the phthalazinone core. The patent specifies that these compounds can include a range of functional groups such as hydroxy, amino, and various alkyl, aryl, and heterocyclyl groups[4].

Therapeutic Applications

Phthalazinone derivatives are of interest for their potential therapeutic applications. While the patent does not specify particular diseases or conditions these compounds are intended to treat, the structural diversity of these compounds suggests they could be explored for a variety of biological activities.

Claims

The patent includes two main claims that define the scope of the invention:

Claim 1

This claim describes the general structure of the phthalazinone derivatives, including the core phthalazinone ring and the various substituents that can be attached. It specifies the types of groups that can be present at different positions on the ring, such as hydrogen, optionally substituted C1-4 alkyl, C5-6 aryl, and other functional groups[4].

Claim 2

This claim is more specific and describes particular embodiments of the phthalazinone derivatives. It details the combinations of substituents that can be present on the phthalazinone ring, including the formation of fused aromatic rings and spiro-cycloalkyl or heterocyclyl groups[4].

Patent Landscape

Prior Art and References

The patent cites several prior art documents, including U.S. and foreign patents, that describe related chemical compounds and their syntheses. These references indicate the state of the art in the field of phthalazinone chemistry at the time of the patent application[4].

Litigation and Enforcement

While the specific patent 7,449,464 is not mentioned in recent litigation documents, the broader context of patent litigation in the pharmaceutical industry is relevant. Patents related to pharmaceuticals are often the subject of intense litigation, particularly when generic manufacturers seek to enter the market. The Hatch-Waxman Act and the process of filing Abbreviated New Drug Applications (ANDAs) often lead to patent infringement disputes[2][5].

Expiry and Generic Competition

The patent 7,449,464 is set to expire, which would allow generic manufacturers to produce and market similar compounds without infringing on the original patent. This is a common scenario in the pharmaceutical industry, where the expiry of patents opens up opportunities for generic competition[5].

Impact on the Pharmaceutical Industry

Innovation and Research

Patents like 7,449,464 drive innovation in the pharmaceutical industry by protecting the intellectual property of researchers and companies. This protection allows them to invest in further research and development, knowing that their discoveries will be safeguarded for a period of time[4].

Generic Competition

The eventual expiry of such patents facilitates the entry of generic drugs into the market, which can significantly reduce drug prices and increase accessibility to medications. This balance between innovation and competition is crucial for the advancement of healthcare[5].

Key Takeaways

• Chemical Structure: The patent covers phthalazinone derivatives with specific structural features and substituents.
• Therapeutic Potential: These compounds have potential therapeutic applications, though the patent does not specify particular diseases.
• Claims: The patent includes two main claims defining the general and specific structures of the phthalazinone derivatives.
• Patent Landscape: The patent is part of a broader landscape of pharmaceutical patents, subject to litigation and eventual generic competition.
• Expiry and Impact: The patent’s expiry will open up opportunities for generic manufacturers, balancing innovation with accessibility.

FAQs

What is the main subject of United States Patent 7,449,464?

The main subject is phthalazinone derivatives, which are chemical compounds with potential therapeutic applications.

Who are the inventors of this patent?

The inventors include Niall Morrison Barr Martin, Graeme Cameron Smith, Stephen Philip Jackson, and others affiliated with UK-based research institutions and pharmaceutical companies.

What are the key claims of this patent?

The patent includes two claims: one describing the general structure of the phthalazinone derivatives and another detailing specific embodiments.

What is the significance of this patent in the pharmaceutical industry?

This patent protects the intellectual property of the inventors, driving innovation and research. Its eventual expiry will facilitate generic competition.

When is the patent set to expire?

The exact expiry date is not specified in the provided sources, but patents generally expire 20 years from the filing date, which would be around 2024 for this patent.

Cited Sources

1. US7449464B2 - Phthalazinone derivatives - Google Patents
2. ANDA Litigation Settlements | Hatch-Waxman - Robins Kaplan LLP
3. The BioLoquitur Bulletin - Seyfarth Shaw LLP
4. (12) United States Patent - googleapis.com
5. Case 3:24-cv-10624 Document 1 Filed 11/20/24 Page 1 of 14 PageID

Drugs Protected by US Patent 7,449,464

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	LYNPARZA	olaparib	CAPSULE;ORAL	206162-001	Dec 19, 2014		DISCN	Yes	No	7,449,464		Y	Y
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558-001	Aug 17, 2017		RX	Yes	No	7,449,464		Y	Y
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558-002	Aug 17, 2017		RX	Yes	Yes	7,449,464		Y	Y

Foreign Priority and PCT Information for Patent: 7,449,464

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0305681.9	Mar 12, 2003

International Family Members for US Patent 7,449,464

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1633724		C300726	Netherlands
European Patent Office	1633724		CR 2015 00012	Denmark
European Patent Office	1633724		C20150012 00136	Estonia